A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)

K
Kathy Miller, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Overview

The purpose of this research study is to look at how your tumor responds to treatment with a combination of three drugs: letrozole, trastuzumab, and palbociclib. We will also be looking at the side effects that are associated with this combination of drugs.

Description

This study will look at how subject's tumor responds to treatment with a combination of three drugs: letrozole, trastuzumab, and palbociclib. Researchers will also be looking at the side effects that are associated with this combination of drugs.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    breast cancer
  • Age: Between 18 Years - 100 Years
  • Gender: Female
Updated on 20 Nov 2022. Study ID: 1710739233 (201610019)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center